J.P. Morgan analyst Anupam Rama maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) on August 9 and set a price target of $19.00. The company’s shares closed yesterday at $12.92.
Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Day One Biopharmaceuticals, and Alnylam Pharma. According to TipRanks, Rama has an average return of 3.3% and a 46.69% success rate on recommended stocks.
Kiniksa Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.00.
See today’s best-performing stocks on TipRanks >>
KNSA market cap is currently $897.6M and has a P/E ratio of -7.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Read More on KNSA:
- Raymond James Sticks to Their Buy Rating for Finance of America Companies (FOA)
- Akoya Biosciences (AKYA) Gets a Buy from J.P. Morgan
- J.P. Morgan Reaffirms Their Buy Rating on NanoString Tech (NSTG)
- J.P. Morgan Reaffirms Their Buy Rating on 10x Genomics (TXG)
- J.P. Morgan Sticks to Its Buy Rating for IAC/InteractiveCorp. (IAC)
